肝細胞癌治療の世界市場2021年-2025年

◆英語タイトル:Global Hepatocellular Carcinoma Treatment Market 2021-2025
◆商品コード:IRTNTR44339
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年2月27日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他の地域
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥287,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥345,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥460,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社の本調査レポートでは、世界の肝細胞癌治療市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、治療別(化学療法、近接照射療法、アブレーション療法)分析、顧客状況、地域別状況、企業状況、企業分析などの項目を掲載しています。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の肝細胞癌治療市場規模:治療別(化学療法、近接照射療法、アブレーション療法)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Hepatocellular Carcinoma Drugs Market 2021-2025
Technavio has been monitoring the hepatocellular carcinoma drugs market and it is poised to grow by $ 106.48 million during 2021-2025, progressing at a 4.10% during the forecast period. Our report on hepatocellular carcinoma drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of liver diseases and lifestyle diseases and growing prevalence of lifestyle diseases. In addition, growing prevalence of lifestyle diseases is anticipated to boost the growth of the market as well.
The hepatocellular carcinoma drugs market analysis includes the therapy segment and geographic landscape.
Technavio’s hepatocellular carcinoma drugs market is segmented as below:

By Therapy
• Chemotherapy
• Brachytherapy
• Ablation therapy

By Geographical Landscapes
• North America
• Europe
• APAC
• ROW

This study identifies the increasing product launches as one of the prime reasons driving the hepatocellular carcinoma drug market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on hepatocellular carcinoma drugs market covers the following areas:
• Hepatocellular carcinoma drugs market sizing
• Hepatocellular carcinoma drugs market forecast
• Hepatocellular carcinoma drugs market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatocellular carcinoma drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, and Pfizer Inc. Also, the hepatocellular carcinoma drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/hepatocellular-carcinoma-drugs-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Therapy
o Market segments
o Comparison by Therapy
o Chemotherapy – Market size and forecast 2019-2024
o Brachytherapy – Market size and forecast 2019-2024
o Ablation therapy – Market size and forecast 2019-2024
o Market opportunity by Therapy
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o APAC – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o AbbVie Inc.
o Amgen Inc.
o AstraZeneca Plc
o Bayer AG
o Bristol-Myers Squibb Co.
o Eli Lilly and Co.
o F. Hoffmann-La Roche Ltd.
o Gilead Sciences Inc.
o Johnson & Johnson
o Pfizer Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Other1 – Market share 2020-2025 (%)
• 22: Comparison by Other1
• 23: Chemotherapy – Market size and forecast 2020-2025 ($ million)
• 24: Chemotherapy – Year-over-year growth 2020-2025 (%)
• 25: Brachytherapy – Market size and forecast 2020-2025 ($ million)
• 26: Brachytherapy – Year-over-year growth 2020-2025 (%)
• 27: Ablation therapy – Market size and forecast 2020-2025 ($ million)
• 28: Ablation therapy – Year-over-year growth 2020-2025 (%)
• 29: Market opportunity by Other1
• 30: Customer landscape
• 31: Market share by geography 2020-2025 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2020-2025 ($ million)
• 34: North America – Year-over-year growth 2020-2025 (%)
• 35: Europe – Market size and forecast 2020-2025 ($ million)
• 36: Europe – Year-over-year growth 2020-2025 (%)
• 37: Asia – Market size and forecast 2020-2025 ($ million)
• 38: Asia – Year-over-year growth 2020-2025 (%)
• 39: ROW – Market size and forecast 2020-2025 ($ million)
• 40: ROW – Year-over-year growth 2020-2025 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: AbbVie Inc. – Overview
• 50: AbbVie Inc. – Business segments
• 51: AbbVie Inc. – Key offerings
• 52: AbbVie Inc. – Key customers
• 53: AbbVie Inc. – Segment focus
• 54: Amgen Inc. – Overview
• 55: Amgen Inc. – Business segments
• 56: Amgen Inc. – Key offerings
• 57: Amgen Inc. – Key customers
• 58: Amgen Inc. – Segment focus
• 59: AstraZeneca Plc – Overview
• 60: AstraZeneca Plc – Product and service
• 61: AstraZeneca Plc – Key offerings
• 62: AstraZeneca Plc – Key customers
• 63: AstraZeneca Plc – Segment focus
• 64: Bayer AG – Overview
• 65: Bayer AG – Business segments
• 66: Bayer AG – Key offerings
• 67: Bayer AG – Key customers
• 68: Bayer AG – Segment focus
• 69: Bristol-Myers Squibb Co. – Overview
• 70: Bristol-Myers Squibb Co. – Product and service
• 71: Bristol-Myers Squibb Co. – Key offerings
• 72: Bristol-Myers Squibb Co. – Key customers
• 73: Bristol-Myers Squibb Co. – Segment focus
• 74: Eli Lilly and Co. – Overview
• 75: Eli Lilly and Co. – Business segments
• 76: Eli Lilly and Co. – Key offerings
• 77: Eli Lilly and Co. – Key customers
• 78: Eli Lilly and Co. – Segment focus
• 79: F. Hoffmann-La Roche Ltd. – Overview
• 80: F. Hoffmann-La Roche Ltd. – Business segments
• 81: F. Hoffmann-La Roche Ltd. – Key offerings
• 82: F. Hoffmann-La Roche Ltd. – Key customers
• 83: F. Hoffmann-La Roche Ltd. – Segment focus
• 84: Gilead Sciences Inc. – Overview
• 85: Gilead Sciences Inc. – Product and service
• 86: Gilead Sciences Inc. – Key offerings
• 87: Gilead Sciences Inc. – Key customers
• 88: Gilead Sciences Inc. – Segment focus
• 89: Johnson & Johnson – Overview
• 90: Johnson & Johnson – Business segments
• 91: Johnson & Johnson – Key offerings
• 92: Johnson & Johnson – Key customers
• 93: Johnson & Johnson – Segment focus
• 94: Pfizer Inc. – Overview
• 95: Pfizer Inc. – Business segments
• 96: Pfizer Inc. – Key offerings
• 97: Pfizer Inc. – Key customers
• 98: Pfizer Inc. – Segment focus
• 99: Currency conversion rates for US$
• 100: Research Methodology
• 101: Validation techniques employed for market sizing
• 102: Information sources
• 103: List of abbreviations



【掲載企業】

AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肝細胞癌治療の世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆